severity of infection | characteristics | setting | preferred route | substances |
---|---|---|---|---|
mild | - limited local signs | outpatient | oral | TMP-SMX ± rifampicin |
- no systemic signs | clindamycin*â—Š | |||
- no surgery required | linezolid* | |||
- patient stable | ||||
moderate | - marked local signs | hospitalized, general ward | initially i.v. | linezolid* |
- systemic signs measurable | tigecycline# | |||
- surgery required | daptomycin | |||
- patient stable | vancomycin | |||
sequential oral treatment | linezolid* | |||
clindamycin* â—Š | ||||
TMP-SMX ± rifampicin | ||||
severe | - massive local and/or systemic signs | inpatient, intensive care | initially i.v. | linezolid* |
- surgery required | daptomycin | |||
- patient unstable | [bacteremia] | |||
tigecycline # | ||||
[polymicrobial inf.] | ||||
(vancomycin) | ||||
sequential oral treatment | linezolid* | |||
clindamycin*â—Š | ||||
TMP-SMX ± rifampicin |